PRAME and neoplasm: The specific targeting of PRAME through T-cell receptor (TCR) therapies, leveraging allogeneic HLA T-cell repertoires, has demonstrated potent anti-tumor reactivity in vitro and in vivo, underscoring the antigen’s viability as a focus for advanced immunotherapeutic strategies.